Abbott (ABT) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.
Need a quote from one of our analysts? Email [email protected]
Abbott Laboratories (NYSE:ABT) presented a quarter marked by distinct segment divergence, with medical devices sustaining double-digit organic sales growth and diagnostics constrained by COVID test declines and policy headwinds in China during Q2 2025 (non-GAAP). The company delivered high single-digit organic sales growth and margin expansion (non-GAAP) in the first half of 2025. New product milestones -- including regulatory approvals and clinical trial progress in cardiovascular and biosimilars -- indicate an acceleration of the innovation pipeline, while explicit FX forecasts offer refined visibility to investors.
Source Fool.com
Abbott Laboratories Aktie
94,63 €
0,92 %
Reines Buy-Sentiment für Abbott Laboratories, keine Sell-Einschätzungen in Sicht.
Die Community erwartet für Abbott Laboratories ein Kursziel von 124 €, was eine Steigerung von über 20% gegenüber 94.63 € bedeuten würde.
